In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to establish Protected dosing routine. Supplemental individuals might be enrolled in the identified monotherapy dosign regimen. In Segment B, individuals will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Phase C, https://abbv-744-in-the-treatment68013.onzeblog.com/31950812/abbv-744-in-combination-with-immunotherapy-an-overview